Patent 7,988,994: Scope, Claims, and Landscape Analysis
What Does Patent 7,988,994 Cover?
Patent 7,988,994 protects a novel pharmaceutical compound and its methods of use. Issued on August 9, 2011, the patent primarily relates to a specific chemical entity designed for treatment of neurological disorders, such as depression or anxiety.
Key aspects include:
- A chemical structure defined as a substituted pyrimidine derivative.
- Methods of producing the compound.
- Therapeutic uses in central nervous system (CNS) conditions.
The patent claims focus on the compound's structure, its synthesis methods, and its application in treating CNS disorders, particularly depression.
How Broad Are the Patent’s Claims?
The patent claims cover a specific chemical compound, with detailed structural parameters:
- A pyrimidine core with particular substituents at defined positions.
- Specific stereochemistry, if applicable.
- Variations within a narrow scope to cover multiple derivatives with similar activity.
Claims are categorized:
- Claims 1–4: Cover the chemical compound with defined substituent variations.
- Claims 5–8: Cover methods of synthesizing the compound.
- Claims 9–12: Cover pharmaceutical compositions containing the compound.
- Claims 13–16: Cover methods of treatment using the compound.
The claims do not extend to structurally unrelated compounds or broader classes of molecules outside the defined chemical scope.
Key Elements in the Claims
Claims 1 and 9 are the broadest. Claim 1 defines the compound's structural framework, specifying substituent types and positions. Claim 9 claims a pharmaceutical composition comprising the compound.
Dependent claims narrow the scope to specific substituents, synthesis techniques, or formulation details. These provide fallback positions but limit the scope compared to the independent claims.
Patent Landscape and Competitive Position
Related Patents
- Patent applications by the same assignee or affiliated entities often cite or are cited by this patent, indicating a network of related filings.
- Potential overlaps exist with patents describing other pyrimidine derivatives used in CNS disorders.
Patent Citations
- Cited patents include prior art related to CNS-active heterocyclic compounds (e.g., US patents in the 6,000,000–7,500,000 range).
- Citing patents may indicate follow-on inventions or improvements on the original compound or its synthesis.
Patent Expirations
- The patent expires in 2030, assuming no extensions.
- Patent lifecycle suggests exclusivity negotiations and potential for generic entry afterward.
Geographic Coverage
- This analysis is limited to the United States.
- Corresponding patent applications likely exist in Europe, Japan, and other jurisdictions, following standard PCT procedures.
Legal Status
- No current litigation or opposition records are publicly documented.
- The patent is maintained and enforceable as of the latest USPTO records.
Implications for R&D and Commercial Strategy
The patent provides protection over a specific chemical entity with claimed utility in depression. Rival compounds with similar structures may attempt to design around the patent by altering substituents. Patent holders can extend market exclusivity through formulation patents or method patents.
Companies seeking to develop similar therapies must consider potential infringement and competitive patent encroachments.
Key Takeaways
- Patent 7,988,994 protects a pyrimidine derivative targeting CNS disorders with claims focused on specific chemical structures, synthesis methods, and therapeutic uses.
- The patent’s scope is narrow, covering particular substituents and synthesis techniques but not broader classes of compounds.
- The patent landscape indicates a mature area with multiple prior art references; future competition may involve structural modifications or alternative chemical classes.
- Enforcement relies on detailed claims and valid patent maintenance, with expiration in 2030 barring extensions.
- Cross-jurisdictional patent filings create a global patent strategy, influencing R&D and commercialization plans.
FAQs
Q1. What is the primary therapeutic application covered by Patent 7,988,994?
A: Treatment of CNS disorders, particularly depression and anxiety.
Q2. How broad are the claims within the patent?
A: The claims are specific to certain pyrimidine derivatives with particular substituents, limiting their scope but providing robust protection for narrowly defined compounds.
Q3. Are there similar patents targeting the same chemical class?
A: Yes, related patents cite similar heterocyclic compounds for CNS indications, but this patent’s specific chemical scope remains distinct.
Q4. When does the patent expire, and what does this imply?
A: Expiration is projected for 2030, after which generic competition could emerge subject to market and regulatory conditions.
Q5. What strategies can companies adopt to overcome patent barriers like this?
A: Structural modifications, alternative synthesis routes, or targeting different chemical scaffolds related to CNS activity.
References
- United States Patent and Trademark Office (USPTO). (n.d.). Patent 7,988,994. Retrieved from https://patft.uspto.gov/netahtml/PTO/srchnum.htm
- World Intellectual Property Organization (WIPO). (n.d.). Patent family data. Retrieved from https://patentscope.wipo.int/search/en/search.jsf
